Analysts See $0.08 EPS for Cipher Pharmaceuticals Inc. (CPH)

August 9, 2018 - By Victoria Pittman

Analysts expect Cipher Pharmaceuticals Inc. (TSE:CPH) to report $0.08 EPS on August, 10 before the open.They anticipate $0.15 EPS change or 65.22 % from last quarter’s $0.23 EPS. T_CPH’s profit would be $2.14 million giving it 9.94 P/E if the $0.08 EPS is correct. After having $0.03 EPS previously, Cipher Pharmaceuticals Inc.’s analysts see 166.67 % EPS growth. The stock increased 1.92% or $0.06 during the last trading session, reaching $3.18. About 10,300 shares traded. Cipher Pharmaceuticals Inc. (TSE:CPH) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Cipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology firm in South America, Canada, and the United States. The company has market cap of $84.97 million. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. It has a 13.31 P/E ratio. The firm also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Sitavig, a tablet for the treatment of herpes labialis in immunocompetent adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.